What the enhanced games reveal about doping in sport

A real-world experiment in doping

The enhanced games, held in Las Vegas at the end of May, let athletes compete while openly using an approved list of performance-enhancing drugs. The event was framed as a chance to study doping under semi-controlled conditions rather than pretend it does not happen. That framing matters, because drug testing in traditional sport is far from airtight: testing catches only about one to two percent of samples, and anonymous surveys of athletes report usage rates between roughly twenty-five and fifty percent. If most competitors already assume doping is widespread, an event that monitors rather than bans PEDs offers a rare window into what these drugs actually do.

How much do PEDs actually help

The results were more modest than many expected. Only one swimming record fell, a 50 meter freestyle time that beat the prior record by a few hundredths of a second, and it was set in a banned high-tech suit on top of drug use. Several marquee athletes who publicly promised to dope and chase records underperformed or finished last.

Part of the explanation is physiological. Performance-enhancing drugs tend to help most in short, high-force events like the 50 meter freestyle or raw strength sports, where more muscle mass and power translate directly into results. As events stretch out, technique, pacing, underwater work and skill matter more, and the advantage from drugs fades. A 100 meter or 200 meter freestyle leaves much less room for PEDs to move the needle than a 50 meter sprint does.

Selection bias adds another layer. Many athletes who joined the enhanced games were past their prime or not top performers in their sport to begin with. Elite genetics, training history and coaching still separate a mediocre athlete on drugs from an elite athlete who is clean, which is consistent with an analysis of open powerlifting data showing untested and tested divisions posting remarkably similar totals across weight classes: differences of only a few percent, or in some cases just a few pounds, between the heaviest tested and untested totals ever recorded in the same division.

That comparison cuts against the assumption that untested divisions are dominated by drug use in a way that tested ones are not. It could mean everyone is using something regardless of testing status, or it could mean that federations with more testing attract more prestige, bigger applicant pools and better coaching, which pulls the best athletes toward them anyway. Either way, the gap is far smaller than a simple model of "drugs equal huge advantage" would predict.

Why the hype around new compounds often outpaces the evidence

Part of what makes conversations about doping messy is how quickly rumors about a compound spread compared with how slowly the actual research catches up. One example that came up around the enhanced games was MK677, a small molecule that increases growth hormone and gets lumped in with peptide drugs even though it works differently. It has performed poorly in essentially every clinical trial it has been part of, yet it keeps circulating in doping discussions as if it were a proven performance enhancer. That mismatch between chatter and clinical results is a useful reminder to check whether a compound has actually held up in trials before assuming it explains someone's results.

Why testosterone dosing is easy to get wrong

The conversation extended to testosterone replacement therapy, which shares some of the same dose-response logic as doping. People who start TRT after being genuinely deficient reliably report better gains from training, since correcting a deficiency restores a normal physiological response. Confusion creeps in around trough levels, meaning testosterone levels measured right before the next dose. Most guidelines target a trough somewhere in the middle of the reference range, often around 400 to 600 ng/dL, but when trough levels are actually measured, many people running standard protocols turn out closer to 800 ng/dL. That is a mildly supraphysiological dose, not a wildly dangerous one, but it explains why some people on TRT describe effects that go beyond simply correcting a deficiency.

Doping regimens compound this problem further. Athletes rarely use a single compound in isolation; stacks combine testosterone with other agents, growth hormone and peptides, and those specific combinations are essentially never studied in controlled trials. Anecdotes about what worked persist, but the actual evidence base for most real-world PED stacks is close to nonexistent.

What this means for evaluating performance claims

The enhanced games are a useful reminder that predicting the effect of any drug or supplement on performance requires asking two questions: what is actually the limiting factor in this event or goal, and is the dose realistic compared with what was actually studied. A compound that clearly builds muscle will not help an event limited by technique or endurance, and a dosing protocol that pushes levels well above what guidelines recommend will produce effects that are not representative of typical, monitored use.

Key takeaways

The first year of the enhanced games did not produce the flood of shattered records many expected, and that outcome fits what the underlying physiology and data would predict. Performance-enhancing drugs help most in short, high-force events and pure strength sport, much less in longer or highly technical ones, and selection bias and unmonitored dosing make many real-world claims about their effects difficult to trust at face value.